Advertisement
Advertisement
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
PremiumRatingsAclaris Therapeutics: Promising Pipeline and Strategic Advancements Drive Buy Rating
25d ago
Aclaris Therapeutics Hosts R&D Day for Innovations
Premium
Company Announcements
Aclaris Therapeutics Hosts R&D Day for Innovations
1M ago
Aclaris Therapeutics to host R&D Day on October 14
Premium
The Fly
Aclaris Therapeutics to host R&D Day on October 14
2M ago
Closing Bell Movers: Qorvo, Starbucks jump after quarterly reports
PremiumThe FlyClosing Bell Movers: Qorvo, Starbucks jump after quarterly reports
4M ago
Aclaris announces ATI-2138 trial meets primary, secondary endpoints
Premium
The Fly
Aclaris announces ATI-2138 trial meets primary, secondary endpoints
4M ago
Aclaris Therapeutics Announces Positive Phase 2a Trial Results
Premium
Company Announcements
Aclaris Therapeutics Announces Positive Phase 2a Trial Results
4M ago
Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052
PremiumThe FlyAclaris Therapeutics initiates Phase 1a/1b program for ATI-052
5M ago
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
Premium
Ratings
Aclaris Therapeutics: Promising Pipeline and Strategic Advancements Support Buy Rating
5M ago
Aclaris Therapeutics Approves 2025 Equity Incentive Plan
Premium
Company Announcements
Aclaris Therapeutics Approves 2025 Equity Incentive Plan
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100